Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Oral ibandronate deemed cost-effective treatment for metastatic bone disease
January 19th, 2006
Oral ibandronate was deemed a cost-effective treatment for metastatic bone disease from breast cancer. "Ibandronate is the first third-generation bisphosphonate to have both oral and intravenous (i.v.) efficacy. An incremental cost-effectiveness model compared oral ibandronate with i.v. zoledronic acid and i.v. generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i.v. chemotherapy. A global economic model was adapted to the UK National Health Service (NHS), with primary outcomes of direct healthcare costs and quality-adjusted life years (QALYs)," investigators in England reported. "Efficacy, measured as...
Source: Women's Health Weekly (2006-01-19)
|
